ŞBŞule Mine Bakanay

Şule Mine Bakanay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Şule Mine Bakanay has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Manifestations, Treatment Characteristics and Clinical Outcome in Patients with Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in the Real-World Setting: An Interim Analysis of the Turkish aTTP Registry

    by Sema Karakuş, Şule Mine Bakanay, Sevgi Kalayoğlu Beşişik, Ahmet Emre Eşkazan, Orhan Ayyıldız, Emel Gürkan, Ozan Salim, Volkan Karakuş, Nil Güler, Muzaffer Keklik, et al.

    This study aimed to investigate the clinical manifestations, treatment patterns and clinical outcomes in patients with iTTP across Türkiye via an interim analysis of the Turkish iTTP registry. A total of 215 patients with iTTP (median age at diagnosis 41 years, 58.6% female) diagnosed between 2001 and 2023 were retrospectively analyzed in the interim analysis of the prospective noninterventional observational multicenter iTTP registry study conducted at 19 tertiary hematology centers. Data on patient demographics, disease characteristics on initial admission, treatment characteristics, and responses, exacerbations/relapses, and the survival outcome were registered via electronic case report forms. Infection (15.0%), new drug initiation (9.7%), and pregnancy/postpartum (6.3%) within 3 weeks before diagnosis were the most prevalent potential triggers. Patients presented more commonly with systemic/constitutional (fatigue 68.8%; fever 18.1%) and neurologic (headache 40.0%, vertigo 32.1%), followed by hemorrhagic, gastrointestinal, renal, and cardiovascular manifestations. Based on the PLASMIC risk scoring, 77.8% of patients were initially at high risk for TTP. The initial treatment was commenced within the first 48 hours of hospital admission in 64.1% of patients (36.2% on the day of admission). Treatment was mainly based on TPE exchange (92.1%) and steroids (63.7%), while rituximab was used in 15.8% of patients. The clinical response rate was 79.9%, and clinical remission was achieved in 68.2% of patients. As for the ADAMTS13 levels, partial and complete responses were achieved in 17.7% and 14.6%, respectively. During a median of 30 months (range, 0.1 to 262.4 months) follow-up, 35 patients experienced exacerbations/relapses. Mortality occurred in 11 (5.5%) patients and was found to be disease-related in 6 (3.0%). This interim analysis of the nationwide Turkish iTTP registry study provided valuable data on the real-world clinical practice in the diagnosis and management of iTTP at different hematology clinics across the country.


  • Open Access

    Does CD47 expression have prognostic significance in classical Hodgkin lymphoma?

    by Aydan Kiliçarslan, Gülnaz Kurt Çevi̇k, Mehmet Doğan, Ayşegül Aksoy Altinboğa, Funda Ceran, Şule Mi̇nE Bakanay Öztürk, Gülşah Efeci̇k

    Background/aimHodgkin Lymphoma (HL) is highly treatable, but new chemotherapy agents are needed for patients with progression or recurrence. CD47 regulates anti-phagocytic activity by signaling through the SIRPα (signal regulatory protein alpha) pathway on macrophages. This study aims to assess the expression of CD47 in HL cases and explore its relationship with Epstein-Barr Virus (EBV) status and the International Prognostic Index (IPI).Materials and Methods120 patients diagnosed with Classical HL, characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells, for whom IPI scores were available. Demographic data and EBV status were retrieved from hospital records. CD47 immunohistochemical expression in HRS cells was evaluated based on its prevalence and intensity. The product of these two values was used to calculate the CD47 expression score.ResultsOf the 120 cases, 76 (63.33%) were male and 44 (36.66%) were female, with an average age of 38.77 years. EBV ISH test results were available for 93 cases, of which 48 (51.61%) were positive. CD47 expression was 67% on average, and cases were categorized based on CD47 expression scores of ≤6 and >6 and IPI scores of ≤2 and >2. No significant relationship was found between CD47 expression score and age(p:0,990), gender(p: 0.086), EBV status(p: 0.374), or IPI score(p: 0.805). However, higher IPI scores were significantly associated with increased EBV positivity (p: 0.041).ConclusionCD47 was widely expressed, but no significant relationship with clinical parameters was observed. Further studies are required to validate its role as a biomarker.


  • Open Access

    Comparison of low dose cytosine arabinoside, azacitidine and azacitidine venetoclax combination treatment as remission induction in elderly acute myeloid leukemia patients

    by Ferda Can, Aysun Yikilmaz, Derda Gokce, Tekin Güney, Sema Akinci, Sule Mine Bakanay, İmdat Di̇lek

    Aims: Low-intensity therapies are widely preferred in the treatment of advanced age, fragile acute myeloid leukemia (AML) patients. In this study, we aimed to compare hematological recovery rates after first cycle chemotherapy and overall survival for advanced aged AML patients treated with azacitidine (AZA) or low dose cytosine arabinoside (LDCA) or venetoclax (Ven) with AZA combination. Methods: Ninety-one patients were retrospectively analyzed. Results: Forty-one patients treated with LDCA, 30 patients treated with AZA and 20 patients treated with AZA+Ven were included in the study. Patients who received these three treatments and who achieved response and did not receive any other treatment during the follow-up period were included in the study. Median age at diagnosis was 70. The percentage of patients who achieved neutrophil recovery after the first cycle was 27%, 73% and 50% of the patients treated with LDCA, AZA and AZA+Ven respectively. The rate of patients who achieved platelet recovery was 60%, 80%, 70% respectively. Erythrocyte transfusion independency was 54% for LDCA patients, 73% for AZA patients and 60% for combination therapy. Overall survival was longer in patients receiving AZA+Ven than other treatment groups while grade 3-4 infections were more common in the first cycle of the treatment. Conclusion: According to our study, patients treated with AZA had better platelet and neutrophil recovery rates with also longer overall survival than patients treated with LDCA, but total overall survival was superior in AZA+Ven combination. Hypomethylating agents with venetoclax is a preferable treatment option in elderly AML patients.

  • Open Access

    Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels

    by Funda Ceran, Sema Akıncı, Mehmet Ali Uçar, Gülten Korkmaz, Mehmet Gündüz, Büşranur Çavdarlı, Şule Mine Bakanay, Mesude Falay, Simten Dağdaş, İmdat Dilek, et al.

    Objective: Achieving an early molecular response (EMR) is crucial for improving the prognosis of patients with chronic myeloid leukemia (CML). The halving time (HT) and reduction ratio (RR) of BCR::ABL1 transcript levels have recently emerged as additional prognostic indexes besides the BCRABL1 International Scale (IS). We aimed to investigate the prognostic role of BeR:ABL1 transcript levels, HT, and RR on molecular response kinetics at 3 months in patients with newly diagnosed chronic-phase (CP)-CML. Materials and Methods: Forty patients with CP-CML who received first-line imatinib treatment were included in this study. BCR::ABL1 transcript levels and molecular responses at baseline and at 3, 6, 12, and 24 months of treatment were evaluated retrospectively. Major molecular response (MMR) at 12 months and event-free survival (EFS) were determined as primary endpoints and the effects of treatment kinetics on these parameters were examined. Results: Of the 40 patients, BCR:ABL1 IS was <= 10% at 3 months in 72.5%, representing EMR. The rate of event occurrence was 45.50/u in patients with BCR:ABL1 IS of >10%, whereas it was 6.9% in those with BCRABL1 IS of 10% (p=0.004). MMR was detected in 62.1% of the patients with EMR and in 9.1% of those without EMR (p=0.003). The cut-off value for achieving MMR was 24 days for HT and 0.04 for RR. Deep molecular response (DMR) at 24 months was associated with HT of 24 days and RR of 0.04. EFS was found to be significantly better in the group with BCRABL1 IS of 100/c) and HT of 24 days (p=0.001) and in the group with BCRABL1 IS of <= 10% and RR of < 0.04 (p=0.007) compared to others. Conclusion: Our findings revealed that MMR could be predicted via EMR as well as by HT and RR. Additionally, HT of 24 days and RR of <= 0.04 were more important than BCR::ABL1 IS of <= 10% in achieving DMR at 24 months, and the combination of BCRABL1 IS of <= 10% with both HI of <= 24 days and RR of <= 0.04 has the best predictive value for EFS.


  • Open Access

    A Rare Lymphoproliferative Disease: Castleman Disease

    by Eren Gündüz, Nihal Özdemir, Şule Mine Bakanay, Sema Karakuş

    Castleman disease is a rare lymphoproliferative disease also known as angiofollicular lymph node hyperplasia. It is classified as hyaline vascular and plasmacytic variants histologically but characteristics of both types can coexist. Most unicentric cases of the disease are hyaline vascular while most multicentric cases are of the plasmacytic type. Although the pathogenesis is not completely understood, the role of interleukin (IL)-6 in unicentric disease and the roles of IL-6 and human herpes virus-8 in multicentric disease are well defined. Unicentric disease is typically localized and symptoms are minimal and treated locally. Multicentric disease is systemic and clinically characterized by generalized lymphadenopathy, splenomegaly, anemia, and systemic inflammatory symptoms. Systemic therapies are primarily given. Several malignant diseases including lymphomas, POEMS syndrome, follicular dendritic cell sarcomas, paraneoplastic pemphigus, Kaposi sarcoma, and amyloidosis can be associated with Castleman disease. In this paper, recent information about Castleman disease, which is a rare disease, is summarized.


  • The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma

    by Vedia Ozturk, Aysun Senturk Yikilmaz, Aydan Kilicarslan, Sule Mine Bakanay, Sema Akinci, İmDat Dilek


  • Effect of Treatment on the Muscle Mass and Response to Therapy in Hodgkin’s Lymphoma

    by Selin Küçükyurt, Burak Bi̇lGi̇n, Melike Meti̇n Ruşen, Aysun Şentürk Yikilmaz, Servihan Ünal, Mehmet Gündüz, Sema Akinci, Şule Mine Bakanay, İmDat Di̇lEk